Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Radiother. Kim, & Blakeney, ). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kumar,. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiobiological. (). Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. Slotman BJ, Senan S. SLOTMAN B, SENAN S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Experiences of case managers in providing. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Quality of life. Treatment of stage I NSCLC in elderly patients: a. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. J Thorac Oncol. , & Reijneveld, S. . Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.